An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quanterix (NASDAQ: QTRX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results. The press release will be issued on May 7, 2024, after the market closes. Interested investors can access the webcast and dial-in information on the Quanterix website.
Quanterix (NASDAQ: QTRX) terrà una conferenza telefonica l'8 maggio 2024 per discutere i risultati finanziari del primo trimestre del 2024. Il comunicato stampa sarà pubblicato il 7 maggio 2024, dopo la chiusura del mercato. Gli investitori interessati possono accedere al webcast e trovare le informazioni per partecipare tramite il sito web di Quanterix.
Quanterix (NASDAQ: QTRX) organizará una llamada de conferencia el 8 de mayo de 2024 para discutir los resultados financieros del primer trimestre de 2024. El comunicado de prensa se emitirá el 7 de mayo de 2024, después del cierre del mercado. Los inversores interesados pueden acceder al webcast e información para llamar en el sitio web de Quanterix.
Quanterix (NASDAQ: QTRX)는 2024년 5월 8일에 2024년 1분기 재무 결과에 대해 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다. 보도 자료는 2024년 5월 7일 시장 마감 후 발표될 예정입니다. 관심 있는 투자자는 Quanterix 웹사이트에서 웹캐스트와 전화 접속 정보를 확인할 수 있습니다.
Quanterix (NASDAQ: QTRX) organisera une conférence téléphonique le 8 mai 2024 pour discuter des résultats financiers du premier trimestre de 2024. Le communiqué de presse sera publié le 7 mai 2024, après la clôture du marché. Les investisseurs intéressés pourront accéder au webcast et aux informations de connexion sur le site web de Quanterix.
Quanterix (NASDAQ: QTRX) wird am 8. Mai 2024 eine Telefonkonferenz abhalten, um über die Finanzergebnisse des ersten Quartals 2024 zu diskutieren. Die Pressemitteilung wird am 7. Mai 2024 nach Börsenschluss veröffentlicht. Interessierte Investoren können die Webcast- und Einwahlinformationen auf der Quanterix-Website abrufen.
Positive
None.
Negative
None.
BILLERICA, Mass.--(BUSINESS WIRE)--
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results.
Quanterix will issue a press release regarding the first quarter 2024 earnings prior to the conference call on Tuesday, May 7, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/.
To pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).